Chemomab Therapeutics Ltd.
For the period ended Mar 27, 2025. Filed Mar 27, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Mar 27, 2025 · Filed Mar 27, 2025
Use the contents to explore the available documents and sections.
Contents
EXPLANATORY NOTE
On March 27, 2025, Chemomab Therapeutics Ltd. (the “Registrant”) issued a press release titled “Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers”, a copy of which is furnished as Exhibit 99.1 herewith.
This Report on Form 6-K and the press release attached as Exhibit 99.1 to this Report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.